Navigation Links
CoLucid Pharmaceuticals and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan, a Novel Agent for Acute Migraine
Date:10/22/2013

safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. The company's pipeline includes Lasmiditan, a novel treatment for migraine headache. Lasmiditan is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies such as triptans.  Lasmiditan is a member of a novel drug class called "ditans" and, unlike triptans, penetrates the central nervous system (CNS) and selectively targets receptors expressed in the trigeminal pathway.  Lasmiditan does not interact with vasoconstrictor receptors on peripheral blood vessels which are activated by triptans. For more information, please visit CoLucid at www.colucid.com.

ABOUT ILDONG PHARMACEUTICAL CO., LTD.

ILDONG Pharmaceutical Co., Ltd., based in Seoul, Korea, is a leading Korean company focused on the development, manufacturing and marketing of pharmaceuticals and OTC products with sales of $317 million in 2012.  ILDONG, founded in 1941, is known to have leading expertise in various therapeutic categories, including neurology, antibiotics, gastrointestinal, anti-diabetics, cardiovascular and oncology.  For more information, visit ILDONG's website at www.ildong.com.


'/>"/>
SOURCE CoLucid Pharmaceuticals, Inc; ILDONG Pharmaceutical Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 AARP Foundation today announced it has established ... from the severe cold weather that has gripped much of ... those in need; so to support these emergency relief efforts ... $250,000, which could mean up to $500,000 in aid. The ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... Bariatric surgery is recommended by IDF, the International Diabetes ... to a new IDF position paper, bariatric surgeries for ... the long run. According to IDF, the surgery often ... the need for medication. LAP-BAND ® Adjustable Gastric ...
... July 25, 2011 Lutonix today announced the first patient ... randomized trial evaluating the safety and efficacy of the Moxy™ ... the treatment of peripheral arterial disease (PAD).  The first case ... Dr. Jeff Goldstein. LEVANT 2 is the ...
Cached Medicine Technology:Latest Information on Obese Patients with Type 2 Diabetes and LAP-BAND System 2First Patient Enrolled in Lutonix Drug-Coated Balloon Pivotal Trial 2First Patient Enrolled in Lutonix Drug-Coated Balloon Pivotal Trial 3
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit organization ... published a comprehensive review today examining the current state ... The review calls for improved global surveillance strategies to ... recent outbreak of Ebola in West Africa that has ... of Guinea and Liberia. According to the World ...
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
(Date:4/17/2014)... is less than 40 years away from a food ... governments, according to a top scientist at the U.S. ... human history, food production will be limited on a ... energy," said Dr. Fred Davies, senior science advisor for ... become as politically destabilizing by 2050 as energy issues ...
(Date:4/17/2014)... Johnston, whose work has transformed cancer care in Northern ... European Academy of Cancer Sciences., The Academy, which was ... highly distinguished oncologists and cancer researchers which aims to ... Europe. , Professor Johnston, whose leadership has seen cancer ... of the UK league table to near the top, ...
(Date:4/16/2014)... , PHOENIX, Ariz. April 15, 2014 The ... Arizona philanthropists at their annual Founders Dinner for their ... cancer. The event took place March 28 in Scottsdale. ... & Catherine Ivy Foundation, received TGen,s John S. McCain ...
Breaking Medicine News(10 mins):Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... Focus is system that regulates blood pressure and fluid ... News) -- New research is shedding some light on ... cause miscarriage and death in pregnant women. , "Preeclampsia ... 10 percent of all pregnancies in the United States," ...
... (FA) is a rare and dangerous disease, new laboratory research ... shows it may lead researchers toward clues in more common ... a study published in the Sept. 11 issue of the ... proteins to DNA damage sites is controlled by replication in ...
... the biggest student drinking problems have so far failed to turn ... in the September issue of the Journal of Studies on ... students, alcohol habits showed little change over a dozen years. In ... two weeks; in 2005, 56 percent said the same. And although ...
... blind and visually impaired often rely on others to provide ... with this method is that it doesn,t give them the ... Lahav of Tel Aviv University,s School of Education and Porter ... to the blind, Dr. Lahav has invented a new software ...
... Administration,s (FDA) recent decision to approve the radioimmunotherapy (RIT) ... lymphoma (NHL). "This is welcome news for ... Ph.D., president of SNM and director of nuclear medicine ... "We,ve known for some time that RIT works extremely ...
... Television journalist Veronica ... and now directs her brother,s story to the White House , ... Los Angeles, CA (PRWeb) September 10, 2009 -- After ... brought the tale of her brother Eric,s tragic battle against health care red tape to ...
Cached Medicine News:Health News:Research Seeks Cause of Preeclampsia 2Health News:Replication at DNA damage sites highlights Fanconi anemia and breast cancer proteins 2Health News:Heavy-drinking colleges showing no improvements 2Health News:Virtual maps for the blind 2Health News:Virtual maps for the blind 3Health News:SNM applauds FDA's decision to approve Zevalin 2Health News:Television Journalist Veronica De La Cruz Brings Her Brother's Story from L.A. to White House in Fight for Health Care Reform 2Health News:Television Journalist Veronica De La Cruz Brings Her Brother's Story from L.A. to White House in Fight for Health Care Reform 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: